RESUMO
Clinical, immunological and DNA diagnostic examinations of 101 patients with chronic generalized parodontitis and peptic ulcer have revealed similar features of immunological disorders of gastric and oral mucosa and the role of Helicobacter pylori.
Assuntos
Mucosa Gástrica/imunologia , Helicobacter pylori/isolamento & purificação , Imunidade Celular/imunologia , Imunoglobulinas/imunologia , Mucosa Bucal/imunologia , Periodontite , Úlcera Gástrica , Adolescente , Adulto , Doença Crônica , DNA Bacteriano/análise , Endoscopia Gastrointestinal , Seguimentos , Mucosa Gástrica/microbiologia , Mucosa Gástrica/patologia , Helicobacter pylori/genética , Humanos , Técnicas Imunoenzimáticas , Imunoglobulinas/metabolismo , Pessoa de Meia-Idade , Mucosa Bucal/microbiologia , Mucosa Bucal/patologia , Periodontite/complicações , Periodontite/imunologia , Periodontite/microbiologia , Reação em Cadeia da Polimerase , Prognóstico , Saliva/imunologia , Saliva/metabolismo , Úlcera Gástrica/complicações , Úlcera Gástrica/imunologia , Úlcera Gástrica/microbiologiaRESUMO
AIM: Analysis of cytostatic therapy effects on expression of gene MDR-1 in hemopoietic cells of patients with acute leukemia (AL) in complete clinicohematological remission (CCHR). MATERIALS AND METHODS: The study included 48 AL patients. 27 of them were untreated, 25 were resistant to or had recurrent AL. 4 patients were followed up. Bone marrow mononuclear fraction was investigated. Expression of MDR-1 gene in the cells was evaluated at hybridization. RESULTS: High expression of MDR-1 gene occurred in leukemic blast cells either upon achievement of CCHR or at least 6 months after its onset. When using schemes of chemotherapy containing two potential inductors of gene MDR-1, expression of this gene was registered significantly more frequently than in using schemes based on one inducing drug (p < 0.05). Frequency of occurrence of enhanced expression of gene MDR-1 in leukemic blasts significantly correlated with frequency of CCHR (p < 0.05). Correlation between occurrence of the gene's expression in normal hemopoietic cells in CCHR and occurrence of early AL recurrences was not found. CONCLUSION: The findings may facilitate design of new AL treatment programs.
Assuntos
Células da Medula Óssea/citologia , Regulação Leucêmica da Expressão Gênica/genética , Genes MDR/genética , Hematopoese/genética , Leucemia Mieloide Aguda/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Protocolos de Quimioterapia Combinada Antineoplásica/antagonistas & inibidores , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Células da Medula Óssea/efeitos dos fármacos , Resistência a Múltiplos Medicamentos/genética , Resistencia a Medicamentos Antineoplásicos/genética , Regulação Leucêmica da Expressão Gênica/efeitos dos fármacos , Genes MDR/efeitos dos fármacos , Hematopoese/efeitos dos fármacos , Humanos , Hibridização In Situ , Leucemia Mieloide Aguda/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Indução de Remissão , Fatores de TempoRESUMO
AIM: To elucidate prognostic value of MDR-1 gene expression in patients with chronic myeloid leukemia (CML). MATERIALS AND METHODS: The MDR-1 gene expression was studied by in situ hybridization in hemopoietic cells of 63 Ph-positive CML patients in different phases of the disease. The survival of the patients and duration of the chronic phase (CP) were evaluated using the Caplan-Meyer method. RESULTS: MDR-1-positive patients had a shorter survival (p < 0.01) and CP (p < 0.05) than negative ones. MDR-1 gene overexpression has no impact either on the survival or duration of AP and BP (p < 0.05). Moreover, the MDR-1 gene overexpression is not dependent either on the previous treatment or other prognostic markers. CONCLUSION: Overexpression of MDR-1 gene is an independent prognostic factor and an additional parameter to Sokal's scores.
